Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 2
1998 3
1999 10
2000 5
2001 4
2002 13
2003 13
2004 9
2005 7
2006 9
2007 11
2008 13
2009 14
2010 11
2011 12
2012 15
2013 16
2014 25
2015 14
2016 12
2017 14
2018 12
2019 11
2020 15
2021 12
2022 6
2023 10
2024 5
2025 7
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.
de Bie RMA, Katzenschlager R, Swinnen BEKS, Peball M, Lim SY, Mestre TA, Perez Lloret S, Coelho M, Aquino C, Tan AH, Bruno V, Dijk JM, Heim B, Lin CH, Kauppila LA, Litvan I, Spijker R, Seppi K, Costa J, Sampaio C, Fox SH, Silverdale MA. de Bie RMA, et al. Mov Disord. 2025 May;40(5):776-794. doi: 10.1002/mds.30162. Epub 2025 Mar 8. Mov Disord. 2025. PMID: 40055961 Free PMC article. Review.
OBJECTIVE: To update evidence-based medicine recommendations for treating motor fluctuations of Parkinson's disease (PD). BACKGROUND: The International Parkinson and Movement Disorder Society (MDS) Evidence Based Medicine in Movement Disorders Committee recommendations for …
OBJECTIVE: To update evidence-based medicine recommendations for treating motor fluctuations of Parkinson's disease (PD). BACKGROUND: …
Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R. Cacabelos R. Int J Mol Sci. 2017 Mar 4;18(3):551. doi: 10.3390/ijms18030551. Int J Mol Sci. 2017. PMID: 28273839 Free PMC article. Review.
Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other symptomatic treatments including dopamine agonists (amantadine, apomorphine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, r …
Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other sym …
Ropinirole.
Rewane A, Patel P, Nagalli S. Rewane A, et al. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 32119419 Free Books & Documents.
Ropinirole is a drug that targets D2 receptors to manage Parkinson disease (PD) and restless leg syndrome. ...This mechanism maximizes the "on" time and minimizes the "off" time associated with disease progression, making ropinirole an attractive option for m …
Ropinirole is a drug that targets D2 receptors to manage Parkinson disease (PD) and restless leg syndrome. ...This mechanism m …
Dopamine agonists.
Factor SA. Factor SA. Med Clin North Am. 1999 Mar;83(2):415-43, vi-vii. doi: 10.1016/s0025-7125(05)70112-7. Med Clin North Am. 1999. PMID: 10093586 Review.
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole. ...Dopamine ha …
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agent …
Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel MD. Kuzel MD. Am J Health Syst Pharm. 1999 Feb 1;56(3):217-24. doi: 10.1093/ajhp/56.3.217. Am J Health Syst Pharm. 1999. PMID: 10030505 Review.
Ropinirole was as effective as levodopa in patients with earlier stages of PD. In one subset of patients with advanced PD not adequately controlled by levodopa, adjunctive ropinirole was more effective than placebo and bromocriptine. ...Ropinirole …
Ropinirole was as effective as levodopa in patients with earlier stages of PD. In one subset of patients with advanced PD …
Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease.
Naz F, Rahul, Fatima M, Naseem S, Khan W, Mondal AC, Siddique YH. Naz F, et al. Neuropharmacology. 2020 Oct 15;177:108216. doi: 10.1016/j.neuropharm.2020.108216. Epub 2020 Jul 21. Neuropharmacology. 2020. PMID: 32707222 Review.
The present study investigates the neuro-protective role of synthesized ropinirole silver nanocomposite (RPAgNC) in Drosophila model of PD. alpha-synuclein accumulation in the brain of flies (PD flies) leads to the damage of dopaminergic neurons, dopamine dep …
The present study investigates the neuro-protective role of synthesized ropinirole silver nanocomposite (RPAgNC) in Drosophila model …
Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease.
Hattori N, Mochizuki H, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Hattori N, et al. Mov Disord. 2020 Sep;35(9):1565-1573. doi: 10.1002/mds.28071. Epub 2020 May 12. Mov Disord. 2020. PMID: 32396257 Clinical Trial.
METHODS: PD patients using levodopa received ropinirole patch (up to 64 mg/d), ropinirole tablets (up to 16 mg/d), or placebo once-daily (double-dummy technique). ...Ropinirole patch can be an alternative option for PD patients. 2020 Internati …
METHODS: PD patients using levodopa received ropinirole patch (up to 64 mg/d), ropinirole tablets (up to 16 mg/d), or p …
A review of ropinirole prolonged release in Parkinson's disease.
Nashatizadeh MM, Lyons KE, Pahwa R. Nashatizadeh MM, et al. Clin Interv Aging. 2009;4:179-86. doi: 10.2147/cia.s3358. Epub 2009 May 14. Clin Interv Aging. 2009. PMID: 19503779 Free PMC article. Review.
In a randomized, double-blind, non-inferiority, crossover study, ropinirole prolonged release was shown to have comparable efficacy and tolerability to immediate release ropinirole in early PD patients, with significantly greater compliance. ...This manuscrip …
In a randomized, double-blind, non-inferiority, crossover study, ropinirole prolonged release was shown to have comparable efficacy a …
Dopaminergic agonists in Parkinson's disease.
Alonso Cánovas A, Luquin Piudo R, García Ruiz-Espiga P, Burguera JA, Campos Arillo V, Castro A, Linazasoro G, López Del Val J, Vela L, Martínez Castrillo JC. Alonso Cánovas A, et al. Neurologia. 2014 May;29(4):230-41. doi: 10.1016/j.nrl.2011.04.012. Epub 2011 Jul 2. Neurologia. 2014. PMID: 21724302 Free article. Review. English, Spanish.
BACKGROUND: Non-ergoline dopamine agonists (DA) are effective treatments for Parkinson's disease (PD). This review presents the pharmacology, evidence of efficacy and safety profile of pramipexole, ropinirole, and rotigotine, and practical recommendations are given …
BACKGROUND: Non-ergoline dopamine agonists (DA) are effective treatments for Parkinson's disease (PD). This review presents the pharm …
Dopamine agonists in Parkinson's disease.
Yamamoto M, Schapira AH. Yamamoto M, et al. Expert Rev Neurother. 2008 Apr;8(4):671-7. doi: 10.1586/14737175.8.4.671. Expert Rev Neurother. 2008. PMID: 18416667 Review.
Pramipexole has shown benefit in improving depressive symptoms in PD. Ropinirole and pramipexole have both demonstrated a reduction in the rate of loss of nigrostriatal innervation as determined by imaging in PD patients, when compared with levodopa. Thus, do …
Pramipexole has shown benefit in improving depressive symptoms in PD. Ropinirole and pramipexole have both demonstrated a redu …
284 results